- MeSH
- Humans MeSH
- Genital Neoplasms, Female * epidemiology prevention & control MeSH
- Diagnostic Screening Programs MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Review MeSH
- Geographicals
- Czech Republic MeSH
- Publication type
- Meeting Abstract MeSH
- Publication type
- Meeting Abstract MeSH
UNLABELLED: An updated Council of the EU recommendation on cancer screening was adopted in December 2022 during the Czech EU presidency. The recommendation included prostate cancer as a suitable target disease for organised screening, and invited countries to proceed with piloting and further research. To support further discussions and actions to promote early detection of prostate cancer, an international conference in November 2022 (Prostaforum 2022) resulted in a joint declaration. Here we describe the EU policy background, summarise the preparation of the declaration and the key underlying evidence and expert recommendations, and report the text of the declaration. The declaration summarises the striking inequalities in prostate cancer burden in Europe and calls on all stakeholders to consider and support concrete steps for advancement of organised early detection of prostate cancer. Our aim is to request endorsement of the text and potential initiation of practical actions by all stakeholders to support the aims of the declaration. PATIENT SUMMARY: Prostate cancer is among the most frequent cancers and is one of the most common causes of cancer death among men. The European Union has recommended new pilot programmes for prostate cancer screening. The Prostaforum 2022 declaration invites all stakeholders to support this new recommendation with specific steps.
- Publication type
- Journal Article MeSH
V průběhu českého předsednictví v Radě Evropské unie bylo v prosinci 2022 schváleno doporučení Rady o screeningu nádorových onemocnění. Jedná se o aktualizaci doporučení Rady z roku 2003, které pomohlo formovat zdravotní politiku ČR i dalších členských zemí, nicméně vyžadovalo aktualizaci dle nejnovějších vědeckých poznatků. Schválené doporučení Rady obsahuje šest diagnóz nádorových onemocnění. Ke screeningu karcinomu prsu, děložního hrdla a tlustého střeva a konečníku se nově řadí i screening nádorů plic, prostaty a žaludku, přičemž technické specifikace těchto screeningů budou dále upřesněny v klinických doporučených postupech vydávaných Evropskou komisí. Do značné míry je toto doporučení Rady v ČR již implementováno, další postup bude diskutován mezi Ministerstvem zdravotnictví ČR, odbornými společnostmi a dalšími aktéry v rámci struktur Národního screeningového centra ÚZIS ČR.
During the Czech Presidency of the Council of the European Union, a recommendation on cancer screening was approved in December 2022. This is an update of the 2003 recommendation, which helped shape health policy in the Czech Republic and other member states; update according to the latest scientific evidence had nevertheless been recommended. The approved recommendation includes six cancer diagnoses. Screening for breast, cervical and colorectal cancer was complemented by screening for lung, prostate and gastric cancer; the technical specifications of these screenings will be further specified in guidelines issued by the European Commission. To a large extent, this recommendation has already been implemented in the Czech Republic, and further steps will be discussed between the Ministry of Health, professional societies and other actors within the structures of the National Screening Centre of the Institute of Health Information and Statistics of the Czech Republic.
- MeSH
- European Union MeSH
- Humans MeSH
- Neoplasms * prevention & control MeSH
- Mass Screening MeSH
- Primary Prevention MeSH
- Check Tag
- Humans MeSH
- Publication type
- Practice Guideline MeSH
- MeSH
- Congresses as Topic MeSH
- Humans MeSH
- Prostatic Neoplasms * diagnosis MeSH
- Diagnostic Screening Programs MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Newspaper Article MeSH
- News MeSH
BACKGROUND: There is no clear evidence whether pirfenidone has a benefit in patients with probable or possible UIP, i.e. when idiopathic pulmonary fibrosis (IPF) is diagnosed with a lower degree of diagnostic certainty. We report on outcomes of treatment with pirfenidone in IPF patients diagnosed with various degrees of certainty. METHODS AND FINDINGS: We followed patients in the multi-national European MultiPartner IPF Registry (EMPIRE) first seen between 2015 and 2018. Patients were assessed with HRCT, histopathology and received a multi-disciplinary team (MDT) IPF diagnosis. Endpoints of interest were overall survival (OS), progression-free survival (PFS) and lung function decline. RESULTS: A total of 1626 patients were analysed, treated with either pirfenidone (N = 808) or receiving no antifibrotic treatment (N = 818). When patients treated with pirfenidone were compared to patients not receiving antifibrotic treatment, OS (one-, two- and three-year probability of survival 0.871 vs 0.798; 0.728 vs 0.632; 0.579 vs 0.556, P = 0.002), and PFS (one-, two- and three-year probability of survival 0.597 vs 0.536; 0.309 vs 0.281; 0.158 vs 0.148, P = 0.043) was higher, and FVC decline smaller (-0.073 l/yr vs -0.169 l/yr, P = 0.017). The benefit of pirfenidone on OS and PFS was also seen in patients with probable or possible IPF. CONCLUSIONS: This EMPIRE analysis confirms the favourable outcomes observed for pirfenidone treatment in patients with definitive IPF and indicates benefits also for patients with probable or possible IPF.
- MeSH
- Anti-Inflammatory Agents, Non-Steroidal pharmacology MeSH
- Idiopathic Pulmonary Fibrosis * diagnosis MeSH
- Humans MeSH
- Lung MeSH
- Probability MeSH
- Pyridones pharmacology MeSH
- Retrospective Studies MeSH
- Vital Capacity MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Publication type
- Meeting Abstract MeSH
- MeSH
- COVID-19 diagnosis epidemiology MeSH
- Epidemics statistics & numerical data MeSH
- Coronavirus Infections diagnosis epidemiology MeSH
- Humans MeSH
- Decision Support Techniques MeSH
- Pandemics statistics & numerical data MeSH
- Antibodies, Viral MeSH
- Check Tag
- Humans MeSH
- Publication type
- Popular Work MeSH
- Interview MeSH
